Home  /  Resource Library  /  A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL)

A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL)

ASH 2020: Results of a trial examining pembrolizumab combined with romidepsin for the treatment relapsed T-cell lymphomas.